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REVISION DE TEMA
Viral hemorrhagic fevers of South America
Robert B. Tesh
Department of Pathology and Center for Tropical Diseases, University of Texas Medical Branch, Galveston,
Texas, USA.
This paper reviews the epidemiology and distinguishing features of three viral hemorrhagic fevers
(dengue hemorrhagic fever, yellow fever and arenaviral hemorrhagic fever) that have emerged as
important public health problems in South America. Although the etiology, natural history and
control of the three diseases are different, their clinical manifestations and histopathology findings
are similar and can be difficult to differentiate. Consequently, early recognition and correct diagnosis
are essential for effective control measures to be initiated.
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Fiebres virales hemorrágicas en Suramérica
El artículo revisa la epidemiología y rasgos distintivos de tres fiebres virales hemorrágicas (dengue
hemorrágico, fiebre amarilla y fiebre hemorrágica por arenavirus), que han emergido como serios
problemas de salud pública en Suramérica. Aunque la etiología, la historia natural y el control de
estas tres enfermedades difieren, sus manifestaciones clínicas y los hallazgos histopatológicos
son similares y pueden ser difíciles de diferenciar. En consecuencia, la detección temprana y el
diagnóstico correcto son esenciales para la aplicación de medidas de control.
Palabras clave: fiebre viral hemorrágica, dengue, fiebre amarilla, epidemiología, patología clínica,
enfermedades por arbovirus.
During the last several decades, three viral
hemorrhagic fevers have emerged as important
public health problems in South America: dengue
hemorrhagic fever, yellow fever and arenaviral
hemorrhagic fever. Although the causative
agents, epidemiology and control of these
diseases are quite different, their clinical
manifestations and histopathological findings are
often similar and difficult to differentiate. Thus,
correct diagnosis and early recognition are
essential for effective control measures to be
initiated.  The emergence of these hemorrhagic
diseases in the region has resulted in part from
changing health priorities, human migration,
population growth and urbanization, and changing
land use patterns. In this review, the epidemiology
of the three hemorrhagic fevers will be reviewed
as well as their distinguishing features and
causes.
Dengue hemorrhagic fever
Dengue is a mosquito-transmitted viral disease
which is now common in tropical and subtropical
regions of South America (1,2). The disease
exists in two clinical forms: classical dengue fever
(CDF) and dengue hemorrhagic fever/dengue
shock syndrome (DHF). There are four dengue
virus serotypes, designated dengue 1, 2, 3 and
4. All are members of the genus Flavivirus, family
Flaviridae. Infection with one dengue virus
serotype provides lifelong protection to the
homologous serotype, but not to the other three
heterologous dengue serotypes. Consequently,
people can have dengue several times in their
life, if they are infected with different dengue virus
serotypes. Each of the four dengue virus
serotypes can produce CDF and DHF. The
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frequency of DHF in persons infected with dengue
virus is relatively low (~1:2,000); but considering
the total number of persons in the world who are
infected with dengue viruses each year (estimated
>100 million), DHF has become a major public
health problem. The reasons why some dengue
virus infections result in DHF, but most do not, is
still uncertain.  Various risk factors have been
proposed to explain the development of DHF;
these include prior infection with other dengue
virus serotypes, immune enhancement, virulence
of the infecting dengue virus genotype, and host
factors (1,3,4).
In the Americas, dengue viruses are transmitted
mainly by Aedes aegypti mosquitoes. The A.
aegypti mosquito is peridomestic and breeds in
artificial containers in and around human
dwellings. In addition, this mosquito preferentially
feeds on humans, which is one reason why it is
such an efficient disease vector. The recent
emergence of DHF in South America can be
explained in large part by the reintroduction of
this vector into areas previously free of the
mosquito, and by human migration, population
growth and urbanization which have created
conditions for enhanced breeding of A. aegypti
(1,2).
Figure 1 shows the distribution of A. aegypti in
the Americas in 1930, in 1970 and in 1998. During
the 1930s, the vector was widely distributed in
cities and towns in tropical America. Then, during
the 1940s and 1950s, the Pan American Health
Organization began an ambitious A. aegypti
eradication program which was originally
designed to permanently eliminate urban yellow
fever from the region. This eradication program
was quite successful, and by 1970, the mosquito
had been eliminated from most countries in South
America.  The elimination of A. aegypti also
stopped dengue virus transmission in areas free
of the vector.  However, during the 1970s, support
for mosquito surveillance and control programs
decreased and many countries were reinfested
with A. aegypti.  This mosquito has now returned
to its original distribution in South America.
Because dengue fever and DHF are now common
in tropical America, these diseases are often over-
diagnosed; consequently, many non-specific
febrile illnesses and hemorrhagic diseases are
incorrectly diagnosed as 'dengue fever' and 'DHF',
respectively. Various studies have demonstrated
that the clinical diagnosis of dengue is not very
accurate (5,6). But, the laboratory confirmation
Figure 1. Distribution of Aedes aegypti in 1930, in 1970 and in 1998 (1).
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of DHF may also be difficult, because it is often
not possible to isolate dengue virus from cases
of DHF and the results of serologic tests on
patients with multiple dengue virus infections are
not easy to interpret. Furthermore, the laboratory
and histopathologic findings in patients with DHF
can mimic those of severe cases of yellow fever
(YF) and arenaviral hemorrhagic fever (AHF). All
three of these diseases can produce leukopenia,
thrombocytopenia, elevated serum transaminase
levels, liver necrosis, and Councilman bodies
(eosinophilic depositions in hepatocytes) (7-17).
This is an important consideration, since correct
diagnosis and early recognition of any of these
diseases is essential for their treatment, as well
as for the appropriate public health response.
Yellow fever
Yellow fever (YF) remains an important cause of
morbidity and mortality in South America. During
the 10-year period from 1986 to 1995, the Pan
American Health Organization reported a total of
2,022 cases of YF from the region (18). Figure 2
shows the number of officially reported YF cases
in South America during that 10-year period by
country. Undoubtedly, these are underestimates,
since milder cases of the disease are not
recognized or reported. Based on the high case-
fatality rates in South America, Monath has
estimated that the true incidence of the disease
in the continent is actually 5-10 times higher (18).
Like dengue, YF is caused by another mosquito-
transmitted flavivirus, the yellow fever virus. The
virus has two distinct cycles in South America: 1)
an endemic or sylvan cycle, thought to involve
monkeys and tree-hole breeding forest
mosquitoes of the genera Haemagogus and
Sabethes; and 2) an epidemic or urban cycle,
involving humans and the domestic mosquito
vector, A. aegypti (19). In fact, it was Jorge Boshell
Manrique who first demonstrated where
Haemagogus mosquitoes lived in the forest
canopy and that they were the principal vectors
of sylvan YF in the Americas (20).
During the 17th., 18th. and 19th. centuries, YF
caused major urban epidemics in Africa,
European port cities and the Americas (19). The
literature suggests that the mortality rate in natural
YF infection is in the range of 20-25%. YF, and
fear of the disease, played an important role in
the settlement and commerce of the New World
during that period. Two years ago, at the
International Congress of Tropical Medicine, Dr.
Hernando Groot gave an interesting historical
account of how an outbreak of YF decimated the
attacking forces of the English pirate Henry
Morgan, and saved Cartagena from capture.
There is just one example of how YF influenced
development and commerce in the New World.
Because of the high mortality resulting from urban
YF epidemics in the Americas and the success
of United States' efforts in controlling the disease
in Cuba and Panama by sanitation and vector
control, the Brazilian Government began a nation-
wide campaign to eradicate A. aegypti in the
1930s (19). The early success of that program
and the introduction of DDT led the Pan American
Sanitary Bureau to initiate the hemisphere-wide
A. aegypti eradication campaign mentioned
before. Between 1947 and 1972, this mosquito
was eliminated from Central America and most
of South America, and urban YF disappeared. The
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Figure 2. Distribution of officially reported yellow fever cases
by country during the decade, 1986-1995 (18).
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last documented A. aegypti-associated epidemic
of YF occurred in Acre State in the Brazilian
Amazon in 1942 (19).
The development of an effective, inexpensive
vaccine also played an important role in
elimination of the urban YF from the Americas.
The 17D YF vaccine was first used in Brazil in
1937; and during the next 30 years, many millions
of persons throughout the Americas received the
vaccine (19). However, following the eradication
of A. aegypti and the disappearance of urban YF,
many South American countries stopped mass
vaccination campaigns. The current policy in most
countries of the region is to wait for the
appearance of sylvan cases, and then to
vaccinate around them in order to contain the
outbreak and prevent spread to urban areas.
Ironically, during the last 25 years as many South
American countries discontinued or de-
emphasized YF vaccination campaigns, the urban
YF vector A. aegypti was reinfesting the same
countries.  The mosquito now occupies its pre-
eradication geographic distribution in the
Americas (figure 1).  The reemergence of dengue
and DHF in South America during the past two
decades attests to the current widespread
distribution and abundance of A. aegypti in the
hemisphere (22). Dengue also is now endemic in
many cities in the Amazon Basin, such as Belem
and Manaus in northern Brazil; Iquitos, Tarapoto
and Pulcalpa in eastern Perú, and Santa Cruz in
eastern Bolivia demonstrating that A. aegypti now
exists in close proximity to areas where sylvan
YF occurs. The continued presence of sylvan YF
in South America constitutes a real threat as a
source of introduction into the urban environment
(23). Given the continuing encroachment of
people into the sylvan habitat of YF fever virus, it
would seem inevitable that the virus will eventually
be introduced into an urban community and that
epidemic YF will reappear.
Two recent outbreaks in Perú and Bolivia illustrate
the potential danger of YF being introduced into
urban areas. Ten or 15 years ago, when the
Sendero Luminoso (Shining Path) terrorist group
was active in the Andean foothills of eastern Perú,
many civilians fled the region. After the defeat of
the Sendero Luminoso group in the early 1990's,
people began to move back into the region and
to reclaim their land. Thousands of contract
workers were recruited from impoverished
highland communities and brought to work
clearing land in the jungle. Most of these people
had never been vaccinated against YF. In 1995,
Perú reported more than 500 cases of YF; most
of these cases were among contracted workers
from the highlands. A similar scenario could occur
in Colombia, when peace finally comes to the
nation and people begin to return to rural areas
where sylvan YF is still present.
Actually, a small urban outbreak of YF occurred
recently in Santa Cruz, Bolivia. In the early 1990's,
the Bolivian government privatized most of the
mines in the highlands. With privatization, many
non-productive mines were closed, and massive
unemployment among miners resulted. Many of
these workers and their families moved to lowland
areas where more jobs were available. Some of
these people settled in Santa Cruz where they
established 'colonias' around the city. They found
work as agricultural workers on surrounding farms
in a region where YF is endemic. Between
December 1998 and June 1999, 6 cases of YF
(5 fatal) were reported among residents of Santa
Cruz, now a city of about one million inhabitants
(24). At the time of this outbreak, dengue was
endemic in Santa Cruz, A. aegypti mosquitoes
were abundant, and the level of YF immunity
among the resident population of the city was only
about 30%. Fortunately, the YF cases were
recognized early, and a mass vaccination
campaign and A. aegypti control program were
rapidly initiated by local authorities. A major
epidemic of urban YF was probably averted. But
this situation illustrates the danger of the
introduction of YF into an urban area where
dengue occurs, and the difficulty in differentiating
DHF from YF initially.
Clinically, the two diseases may be similar:
acutely ill patients with fever, leukopenia and
hemorrhagic manifestations (7-13). Although YF
patients often have icterus, this is not always obvious
in people with dark skin. The histopathological
diagnosis of YF is also sometimes difficult, unless
special staining procedures are used. Typically in
fatal cases of YF, one sees midzonal hepatocyte
necrosis, microvesicular steatosis, pyknotic
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nuclei, and acidophilic or eosinophilic depositions
within the cytoplasmic of dying liver  cells (figure 3).
These eosinophilic depositions or so-called
Councilman bodies were once thought to be
diagnostic of YF; but it is now known that
Councilman-like bodies can be seen in a number of
diseases where liver cell necrosis or apoptosis
occurs. This includes DHF (8,9) and AHF (14-17).
We have recently developed a new hamster
model of fulminant YF, which shows many of the
clinical and pathologic features of the severe
disease in humans (12,21). After infection,
hamsters develop a high YF viremia that peaks
on day 3 and that lasts 5 or 6 days (21). Antibodies
(hemagglu-tination inhibition and IgM) first appear
between day 4 and 5. About 20% of adult
hamsters die from YF infection; death usually
occurs in the animals on day 5 or 6, as in severe
human cases of the disease. These animals also
have elevated serum transminase and bilirubin
levels (21).
Arenaviral hemorrhagic fevers
To date, a total of 17 different indigenous
arenaviruses have been identified in the Americas
(25-27). Most of the New World arenaviruses occur
in South America. In general, they have a rather
restricted geographic distribution; and most of the
viruses are associated with a single vertebrate
species, usually a rodent (25-27). The natural rodent
reservoirs of arenaviruses usually develop a
persistent infection and continuously shed virus in
their urine, feces and saliva (25,28). Human
infection is thought to result primarily from
inhalation of aerosols of infected rodent excreta,
although venereal transmission and nosocomial
infections have also been reported (16,25).
Four of the South American arenaviruses have
been associated with severe hemorrhagic disease
(AHF) in humans (25). Each of these arenaviruses
is associated with a disease of a different name:
Junin virus with Argentine hemorrhagic fever
(AgtHF); Machupo virus with Bolivian hemorrhagic
fever (BHF); Guanarito virus with Venezuelan
hemorrhagic fever (VHF), and Sabia virus with
Brazilian or Sao Paulo hemorrhagic fever. In reality,
the clinical manifestations and laboratory findings
in the four diseases are indistinguishable. After
an incubation period of 7-14 days, AHF begins
insidiously with progressive development of fever,
chills, malaise, anorexia, myalgia and sore throat
(16,25,29). During the first 3-5 days, the signs
and symptoms are indistinguishable from a variety
of other non-specific viral and bacterial illnesses.
As the disease progresses, patients develop
weakness, arthralgia, back pain, nausea,
vomiting, epigastric pain, dizziness, conjunctivitis,
flushed face and bleeding gums. By the 6th. or
7th. day, the patients are usually acutely ill with
dehydration, disorientation and frequently
hemorrhagic and/or neurological manifestations.
If death occurs, it usually results from massive
hemorrhage and/or shock. If the patient survives
this period, improvement begins about the 10th.
or 12th. day and a slow convalescence ensues.
The mortality rates in patients with untreated AHF
range from about 10 to 33%. Mortality rates of
AHF decrease with early hospitalization and
intensive supportive care, including immune
human plasma or the antiviral drug ribavirin (16).
The frequency of the South American AHFs vary
widely, and less is known about their
epidemiology than is known about DHF and YF.
To date, only 4 cases of Sao Paulo hemorrhagic
fever have been reported; two natural cases and
two accidental infections among laboratory
personnel working with Sabia virus (25).
The first documented outbreak of BHF occurred
between 1962 and 1964 in the town of San
Joaquín in the Beni department of northeastern
Bolivia (16,25). About 1,000 human cases
occurred during that initial outbreak. Since that
time, only sporadic cases of BHF have been
reported. However, cases still do occur; we made
an isolate of Machupo virus from a human case
of BHF last year.
The two AHFs that have been most thoroughly
studied are (AgtHF) and VHF. AgtHF was first
recognized as a distinct entity during the 1950s
in an agricultural region north of Buenos Aires
(25). From 1958 to 1994, more than 24,000
human cases were reported with annual totals
ranging from 200-3,000 cases (25). AgtHF affects
mostly adult male agricultural workers. Cases of
the disease occur mainly during the harvest
season, with a peak incidence in May. Since the
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introduction of the Candid-1 vaccine in 1991, the
annual incidence of the disease has decreased
dramatically (25).
VHF was first recognized in 1989 in an agricultural
region of Portuguesa state (29). Between
September 1989 and August 1998, more than 200
cases of VHF were reported. The disease has
occurred in a sporadic cyclical manner; cases
have been reported in every month of the year,
but the majority have occurred in the months of
November, December and January (29). This
period corresponds with the end of the rainy
season and beginning of the dry season in the
endemic region, and it is a period of intense
agricultural activity.  During the past dry season
(November 2001- January 2002), another 30 cases
of the disease were reported. Like the pattern
observed with AgtHF, VHF occurs mainly among
adult male agricultural workers, suggesting that
infection occurs outside of the home in rodent-
infested fields and grasslands (29).
One of the interesting questions about VHF is why
were cases not recognized until 1989. The answer
seems largely related to human migration and
land use patterns in the affected region. During
the period from 1985-2000, there was a major
movement of people into the llanos of Venezuela,
especially Portuguesa and Barinas states. Much
of this land was originally forested; but with
development, the forest was removed and was
replaced by agricultural fields and pastures
(25,30). This ecologic change provided increased
habitat for certain grassland rodents, one being
Zygodontomys brevicauda, the reservoir of
Guanarito virus. Thus, there were increased
numbers of infected rodents, and increased
numbers of susceptible people living in the same
region. A similar pattern was observed in
Argentina when intensive agriculture (soy beans
and corn) was developed in the Pampa region
where AgtHF now occurs (16,25,31). Cultivated
fields and the surrounding grasslands provided
habitat for the rodent reservoirs of Junin virus (31).
The arenaviruses are very old and probably
evolved with their rodent hosts; but when people
change the ecology, allowing an increase in the
abundance of the rodent hosts, the risk of human-
virus contact increases (25).
As noted before, the initial clinical manifestations
of AHF are indistinguishable from a variety of
other non-specific viral and bacterial illnesses
(16,25).  In fact, the first two isolates of Guanarito
virus were made from fatal cases initially
diagnosed as DHF (29). Table 1 shows the clinical
diagnosis of 56 confirmed VHF cases at the time
of the patients' hospitalization (25). Despite the
relative frequency of VHF in the endemic region,
it is a difficult diagnosis to make. Patients with
VHF appear at a clinic or hospital with a 4-5 day
history of progressively severe febrile illness; they
usually have leukopenia and thrombocytopenia,
and sometimes hemorrhagic manifestations are
present.  Laboratory studies may indicate
elevated serum transaminase levels. But, at this
point, the illness cannot be differentiated from
DHF or YF.
Despite the severity of the illness, patients dying of
AHF show surprisingly little pathology. The most
consistent findings at autopsy are in the liver and
have been described as multifocal hepatocytic
necrosis, usually without significant inflammatory
reaction (14,32,33). Focal hepatocyte necrosis can
be seen as well as Councilman bodies. We recently
described a hamster model of AHF, using Pirital
virus. Hamsters inoculated with Pirital virus develop
a progressively severe, fatal illness of about 7 days
duration; the pathologic features are similar to those
observed in fatal human cases of AHF (17). Figure
4 shows a H&E stained section of liver from a
hamster experimentally infected with Pirital virus.
Table 1. Clinical diagnoses in 56 confirmed cases of
Venezuelan hemorrhagic fever at time of patients’
hospitalization.
Diagnosis No. of confirmed
cases of VHF
Viral syndrome 16
Classic dengue fever 11
No diagnosis 7
Venezuelan hemorrhagic fever 6
Hemorrhagic virosis 5
Dengue hemorrhagic fever 4
Tonsilitis/pharyngitis 2
Convulsive syndrome 1
Bronchopneumonia 1
Gastrointestinal hemorrhage 1
Sepsis 1
Febrile syndrome 1
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Seven days after infection focal hepatocytic
necrosis can be seen with scattered acidophilic
bodies.
Because of the non-specific nature and high
mortality of viral hemorrhagic fever, the diagnosis
and etiology are often not determined until
autopsy.  As noted before, the major pathology
observed at necropsy in cases of DHF, YF and
AHF is in the liver. However, using a standard
H&E stain, it is difficult to determine the precise
etiology. Figure 3 shows a liver section from a
fatal case of presumed viral hemorrhagic fever in
Ecuador. It would be difficult for a pathologist to
say with certainty whether this person died of
DHF, YF or AHF. Furthermore, culture of the
affected tissues may not be much more helpful.
Dengue and YF viruses are infrequently cultured
from tissues at the time of death, probably because
the patient already has developed antibodies to the
infecting agent. The arenaviruses can be cultured
from tissues at death; but they usually do not form
viral cytopathic effect in mammalian cell cultures,
so an indirect method (immunofluorescence, RT-
PCR, etc.) must be used to confirm their presence.
Figure 5 shows liver tissue from the same
Ecuadorian patient stained by the immuno-
peroxidise technique, using a YF mouse immune
serum. The brown-staining material within the
infected hepatocytes is YF viral antigen and is
diagnostic. Figure 4 shows an H&E-stained
section of liver from a hamster infected with Pirital
virus. Focal hepatocyte necrosis is visible, but the
Figure 3. Photomicrograph of liver from fatal human case
of yellow fever showing hepatocytic necrosis, microvesicular
steatosis, pyknotic nuclei and eosinophilic depositions
(Councilman bodies) (100X magnification).
Figure 4. Focal hepatic necrosis with scattered eosinophilic
bodies in a hamster, seven days after infection with Pirital
virus (50X).
Figure 5. Immunohistochemical staining for yellow fever viral
antigen (reddish brown color) in liver of fatal yellow fever
case (100X).
Figure 6. Immunohistochemical staining in liver of hamster
infected with Pirital virus; viral antigen appears as diffuse
brown color (model of AHF) (100X).
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etiology is uncertain unless an immunostaining
technique is used. Figure 6 shows a liver section
of the same animal stained with the immuno-
peroxidase method and a Pirital mouse immune
serum.
In summary, three viral hemorrhagic fevers occur
in tropical regions of South America. At present,
DHF is by far the most common; YF and AHF are
less frequent but have a significantly higher
mortality rate. The introduction of YF into an urban
area in tropical America could have grave public
health consequences because of the low level of
immunity among most urban residents of the
region, the abundance and wide distribution of
the mosquito vector, and a relative shortage of
the 17-D vaccine worldwide. AHF is an endemic
disease and does not have the same epidemic
potential as dengue or YF, although a number of
nosocomial outbreaks have been reported among
hospital personnel attending AFH patients (16).
Also AHF is a treatable disease if therapy is
initiated during the first 6 days of the illness (16).
Thus, correct diagnosis and early recognition of
these diseases are essential for effective control
measures to be initiated.
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